Drugs / FX-322
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04120116 | Oct 2019 → Oct 2020 | noise induced hearing loss, sudden sensorineural hearing loss | Frequency Therapeutics | Completed | Missed primary |
| Comparator or background therapy4 trials | ||||||
| Phase 0 | NCT03300687 Comparator | May → Dec 2017 | hearing loss disorder | Frequency Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04629664 Comparator | Nov 2020 → May 2021 | noise induced hearing loss, sensorineural hearing loss disorder, sudden hearing loss disorder | Frequency Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04601909 Comparator | Sep 2020 → May 2022 | noise induced hearing loss, presbycusis, sudden hearing loss disorder | Frequency Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT05086276 Comparator | Oct 2021 → Dec 2022 | noise induced hearing loss, sensorineural hearing loss disorder, sudden hearing loss disorder | Frequency Therapeutics | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-07-17 | Astellas Pharma Inc | Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss astellas.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FX-322 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03300687 ↗ |
| Route | Other | “administered by intratympanic injection” NCT05086276 ↗ |